Glucagon-like Peptide-1 Receptor Agonist Therapy in Cystic Fibrosis-Related Diabetes: Insights From a Pilot Implementation Program.

Abstract

Management of cystic fibrosis (CF)-related diabetes (CFRD) is evolving as the CF population experiences increasing rates of overweight and obesity, particularly with the widespread use of CF transmembrane conductance regulator (CFTR) modulators. This article describes practical insights from implementing a pilot program that evaluated injectable semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1 RA), in adults with CFRD. Our program followed 11 participants over 12 months, revealing important considerations for patient selection, monitoring protocols, and managing adverse effects in this unique population. Although most participants tolerated semaglutide well with clinically meaningful improvements observed in glycemic management, careful screening and close follow-up proved essential. These findings offer practical guidance for diabetes educators and clinicians considering GLP-1 RA therapy as an adjunct to insulin in carefully selected patients with CFRD.